缺氧预处理对乳鼠心肌细胞蛋白激酶C活性的影响

在培养的乳鼠心肌细胞缺氧／复氧模型上,观察了缺氧预处理的细胞保护作用及其对细胞蛋白激酶Ｃ活性和蛋白磷酸化的影响。结果表明,ＡＰＣ可减轻心肌细胞的Ｈ／Ｒ损伤;提高细胞存活率,减少细胞脂质过氧化产物生成及细胞内乳酸脱氢酶和蛋白质漏出。模拟ＡＰＣ的短暂缺氧显著激活ＰＫＣ,使心肌细胞内分子量为６６ｋＤ和３１ｋＤ的蛋白条带＾３２Ｐ掺入增加;ＰＫＣ抑制剂Ｈ７完全消除ＡＰＣ对心肌细胞的保护作用,并抑制了短暂缺氧     

蛋白激酶C参与缺氧预处理的血管平滑肌细胞保护

已知缺氧预处理不仅对心肌细胞,而且对血管床亦有保护作用;但对血管壁细胞是否有直接保护作用,目前尚不清楚。本工作在培养的家兔血管平滑肌细胞（ＶＳＭＣ）缺氧复氧（Ａ／Ｒ）损伤模型上观察缺氧预处理（ａｎｏｘｉｃｐｒｅｃｏｎｄｉｔｉｏｎｉｎｇ,ＡＰＣ）的影响。发现ＡＰＣ能提高Ａ／Ｒ后ＶＳＭＣ存活率,减轻细胞脂质过氧化损伤和钙超载,使用蛋白激酶Ｃ（ＰＫＣ）激动剂ＰＭＡ能模拟,而抑制剂Ｈ７或ｐｏｌｙｍｙｘｉｎＢ能完全消除ＡＰＣ的上述保护作用。提示ＡＰＣ对ＶＳＭＣ的Ａ／Ｒ损伤具有保护作用,其机理可能与ＰＫＣ激活有关     

细支气管肺泡细胞增生和细支气管肺泡细胞癌内生长因子和蛋白激酶C的表达

表皮生长因子（ＥＧＦ）、转化生长因子－α（ＴＧＦα）、表皮生长因子受体（ＥＧＦＲ）和蛋白激酶Ｃ（ＰＫＣ）与细胞生长、增殖分化调节和细胞癌变有密切关系。作者用免疫组织化学方法检测了细支气管肺泡细胞增生（ＢＡＨ）和细支气管肺泡细胞癌（ＢＡＣ）的ＥＧＦ、ＴＧＦα、ＥＧＦＲ和ＰＫＣ表达。结果表明：ＢＡＣ中的ＥＧＦ、ＴＧＦα阳性率和阳性强度以及ＥＧＦＲ、ＰＫＣ阳性强度均明显高于ＢＡＨ。ＢＡＨ的重度不典型增生病例,其ＥＧＦ、ＴＧＦα、ＥＧＦＲ和ＰＫＣ均呈高表达。ＴＧＦα、ＥＧＦＲ和ＰＫＣ三者在ＢＡＣ和ＢＡＨ中的表达存在明显相关性。提示：ＴＧＦα及其受体ＥＧＦＲ和ＰＫＣ是细支气管肺泡细胞增生、恶性转化和肺泡癌细胞失控生长的重要因素。     

RFP_（134）对UMR106细胞EGF受体酪氨酸蛋白激酶的调节作用

以大鼠成骨肉瘤细胞（ＵＭＲ１０６）为模型,研究了表皮生长因子（ＥＧＦ）对其受体酪氨酸蛋白激酶（ＴＰＫ）的调节作用。以本实验室从植物中提取纯化的二萜类活性物质（ＲＦＰ１３４）为诱导分化剂,观察了ＲＦＰ１３４对ＵＭＲ１０６细胞ＥＧＦ受体ＴＰＫ的活性和磷酸化作用的影响,并与ＲＡ和ＲＦＰ１３４＋ＲＡ处理细胞做了比较,结果显示ＥＧＦ与其受体结合后能激活ＴＰＫ,使ＴＰＫ活性增加２倍．ＲＦＰ１３４,ＲＡ,ＲＦＰ１３４＋ＲＡ处理细胞后,分别降低ＥＧＦ诱导的受体ＴＰＫ活性５０％,４３％,５５％,降低磷酸化ＴＰＫ含量５５％,３６％,５３％。从结果中发现无ＥＧＦ刺激的细胞也具有受体ＴＰＫ磷酸化作用,用ＲＦＰ１３４,ＲＡ,ＲＦＰ１３４＋ＲＡ处理细胞,分别降低受体磷酸化ＴＰＫ含量５９％,４０％,５７％,而且我们发现用ＥＧＦ诱导的细胞受体ＴＰＫ含量高于无ＥＧＦ作用的细胞．提示ＵＭＲ１０６细胞本身可能具有受体ＴＰＫ活性,能够引起细胞受体自动磷酸化,ＥＧＦ刺激后ＴＰＫ的磷酸化作用增强,可见ＲＦＰ１３４对ＥＧＦ诱导的ＴＰＫ磷酸化和无ＥＧＦ诱导的受体自动磷酸化都具有明显的抑制作用,（并强于ＲＡ）这可能与在第二信使水平上阻抑ＰＴＰＫ活性密切相关     

PKC、PKA和TPK在血小板激活中的作用

利用~（３２）Ｐ－ＮａＨ_２ＰＯ_４标记猪血小板,然后以ＰＭＡ、凝血酶、ＰＧＥ_１、腺苷等处理,结果表明,随着ＰＭＡ激活ＰＫＣ,血小板发生聚集。３５μｍｏｌ／ＬＰＧＥ_１或１ｍｍｏｌ／ＬｄｂｃＡＭＰ不能抑制５０ｎｍｏｌ／ＬＰＭＡ诱导的血小板聚集,腺苷却能抑制ＰＭＡ诱导的血小板聚集（ＥＣ_（５０）＝０．１ｍｍｏｌ／Ｌ）,ｄｂ－ｃＡＭＰ、腺苷都不能抑制１００ｎｍｏｌ／ＬＰＭＡ诱导的４０ｋＤ蛋白磷酸化。ＰＫＡ激活不能抑制ＰＭＡ激活的ＰＫＣ。在ＰＭＡ、凝血酶激活的血小板中,ＰＫＣ、ＴＰＫ都发生激活,４０ｋＤ底物既是ＰＫＣ的底物又是ＴＰＫ的底物,ＰＫＣ和ＴＰＫ在血小板聚集中起着重要的调节作用。     

酪氨酸蛋白激酶和蛋白激酶C对N-乙酰氨基葡萄糖转移酶V的双重调控

在人肝癌细胞７７２１中研究了酪氨酸蛋白激酶（ＴＰＫ）和蛋白激酶Ｃ（ＰＫＣ）的激活剂［分别为表皮生长因子（ＥＧＦ）和佛波酯（ＰＭＡ）］和各种蛋白激酶抑制剂对Ｎ－乙酰氨基葡萄糖转移酶Ｖ（ＧｎＴ－Ｖ）活力的影响,以探讨ＴＰＫ和ＰＫＣ对ＧｎＴ－Ｖ的调节。结果发现,ＥＧＦ或ＰＭＡ处理细胞４８ｈ后,ＧｎＴ－Ｖ的活力明显增高;蛋白激酶的非特异性抑制剂槲皮素和染料木黄酮（ｇｅｎｉｓｔｅｉｎ）在抑制ＴＰＫ和ＰＫＣ的同时,抑制ＧｎＴ－Ｖ的基础活力,并完全阻断ＥＧＦ或ＰＭＡ对ＧｎＴ－Ｖ的增高作用;ＴＰＫ的特异性抑制剂Ｔｙｒｐｈｏｓｔｉｎ－２５和ＰＫＣ的特异性抑制剂Ｄ－鞘氨醇分别应用时,各自只能部分地取消ＥＧＦ或ＰＭＡ对ＧｎＴ－Ｖ的诱导。但当Ｔｙｒｐｈｏｓｔｉｎ－２５和Ｄ－鞘氨醇同时加入培养基中则可完全阻断ＥＧＦ或ＰＭＡ对ＧｎＴ－Ｖ的诱导激活。蛋白质合成抑制剂环己亚胺和蛋白激酶抑制剂作用相仿,不但可抑制ＧｎＴ－Ｖ的基础活力,也可完全消除ＥＧＦ或ＰＭＡ对ＧｎＴ－Ｖ的激活。以上结果提示ＥＧＦ或ＰＭＡ通过蛋白激酶调节ＧｎＴ－Ｖ的酶蛋白合成,并且ＧｎＴ－Ｖ受到膜性ＴＰＫ和ＰＫＣ的双重调节,其中ｍ－ＴＰＫ较ｍ－ＰＫＣ更为重要。     

RFP134对UMR106细胞EGF受体酪氨酸蛋白激酶的调节作用

以大鼠成骨肉瘤细胞（ＵＭＲ１０６）为模型,研究了表皮生长因子（ＥＧＦ）对其受体酪氨酸蛋白激酶（ＴＰＫ）的调节作用。以及实验室从植物中提取纯化的二萜类活性物质（ＲＦＰ１３４）为诱导分化剂,观察了ＲＦＰ１３４对ＵＭＰ１０６细胞ＥＧＦ受体ＴＰＫ的活性和磷酸化作用的影响。并与ＲＡ和ＲＦＰ１３４＋ＲＡ处理细胞做了比较。结果显示ＥＧＦ与其受体结合后能激活ＴＰＫ,使ＴＰＫ活性增加２倍。ＲＦＰ１３４,ＲＡ,ＲＦＰ     

蛋白激酶C和Na~＋－H~＋交换在ANGⅡ诱发心肌细胞肥大反应中的作用

血管紧张素（ＡＮＧ）Ⅱ在１０－１０－１０－６ｍｏｌ／Ｌ范围内剂量依赖性促进无血清培养新生大鼠心肌细胞蛋白质合成速率。蛋白激酶Ｃ（ＰＫＣ）抑制剂ｓｔａｕｒｏｓｐｏｒｉｎｅ（Ｓｔａｕ２ｎｍｏｌ／Ｌ）对心肌细胞基础状态３Ｈ－Ｌｅｕｃｉｎｅ掺入无明显影响，但Ｓｔａｕ预处理３０ｍｉｎ，则可有效阻断ＡＮＧⅡ（１μｍｏｌ／Ｌ）对细胞蛋白质合成的刺激作用；单纯应用ＰＫＣ激活剂ＰＭＡ（１μｍｏｌ／Ｌ）可使心肌细胞蛋白质合成速率增加，与对照组相比，ＰＭＡ组３Ｈ－Ｌｅｕｃｉｎｅ掺入量增加了４１．０４％。细胞Ｎａ＋－Ｈ＋交换抑制剂Ａｍｉｌｏｒｉｄｅ预处理也能阻断ＡＮＧⅡ刺激３Ｈ－Ｌｅｕｃｉｎｅ掺入细胞蛋白质的作用。以上结果提示ＰＫＣ和Ｎａ＋－Ｈ＋交换的激活，可能是ＡＮＧⅡ诱发的心肌细胞肥大反应的重要胞内信息转导机制。本工作还观察到，阻断细胞Ｎａ＋－Ｈ＋交换后并不影响由ＰＫＣ激活导致的蛋白质合成增加，提示可能存在着ＰＫＣ和Ｎａ＋－Ｈ＋交换彼此相对独立地调节心肌细胞生长的途径。     

谷氨酰胺对体外培养人小肠上皮细胞缺氧复氧损伤的保护作用

应用原代培养人胎小肠上皮细胞（ＩＥＣ）,观察了谷氨酰胺（ＧＬＮ）对缺氧复氧（Ａ／Ｒ）损伤人ＩＥＣ的影响。结果：缺氧６０ｍｉｎ复氧３０ｍｉｎ后,细胞内乳酸脱氢酶（ＬＤＨ）漏出量显著上升,细胞存活率显著下降。预先应用１～５ｍｍｏｌ／ＬＧＬＮ可使Ａ／Ｒ损伤ＩＥＣ细胞存活率升高和细胞内ＬＤＨ漏出量减少,ＧＬＮ作用的最佳剂量为２ｍｍｏｌ／Ｌ。提示ＧＬＮ对人ＩＥＣ具有直接的保护作用,这可能是其整体保护作用机制之一。     

蛋白激酶C的激活转位和它介导的信号通路

蛋白激酶Ｃ是一系列丝氨酸／苏氨酸蛋白激酶家族,已发现了至少十二种同功酶。在静止细胞中,它主要以非活化形式存在于胞浆中,由受体－Ｇ蛋白耦联的ＰＬＣβ激活便裂细胞膜上的磷脂而释放ＤＡＧ;与ＰＫＣ的结合引起了ＰＫＣ的别构激活;而通过其它信号途径激活的ＰＬＤ水解胞膜的磷脂酰胆碱（ＰＣ）产生的磷脂酸经磷脂酸酯酶产生的ＤＡＧ可能是ＰＫＣ持续激活的必要条件。在体外实验中,ＰＫＣ的持续激活是一些细胞分化所必须的。蛋白激酶Ｃ的激活首先引起了它转位到膜,有时转位到核,并在转位后继续保持磷酸化活性,同时对它的下游底物进行磷酸化导致它们的活化。ＰＫＣ可活化ＲａｆＳｅｒ／Ｔｈｒ蛋白激酶及ＮＦ－ｋＢ,介导细胞对外界的反应,包括对核基因表达的调节,引起细胞生长或分化等。由于Ｒａｆ可与活化的Ｒａｓ—ＧＴＰ结合从而定位到胞膜,说明蛋白激酶Ｃ与Ｒａｓ介导的Ｒａｆ－１／ＭＥＫ／ＭＡＰＫ信号通路间存在着“对话”。     

The protective effects of puerarin in cardiomyocytes from anoxia/reoxygenation injury are mediated by PKCε

Puerarin is an isoflavone isolated from traditional Chinese medicine Ge‐gen (Radix Puerariae). Clinical studies have confirmed the cardioprotective effects of puerarin; however, the mechanisms underlying these effects are still unclear. On the basis of previous findings, we hypothesized that puerarin protects cardiomyocytes from ischemia–reperfusion injury via the protein kinase C epsilon (PKCε) (a critical cardioprotective protein) signalling pathway. Neonatal rat primary cardiomyocytes were preconditioned with puerarin or puerarin plus εV1‐2, a selective PKCε inhibitor, prior to anoxia/reoxygenation (A/R) treatment. Western blot analysis showed that expression and activity of PKCε protein in puerarin preconditioned group were both increased compared with the control or A/R group. Subsequent assays showed that preconditioning with puerarin could increase the viability of neonatal rat primary cardiomyocytes treated with A/R, decreased the generation of reactive oxygen species (ROS), loss of mitochondrial membrane potential, cell necrosis and apoptosis induced by A/R injury. However, the protective effects of puerarin completely disappeared in the group pretreated with puerarin plus εV1‐2. Thus, for the first time, we revealed the protective effects of puerarin in cardiomocytes from anoxia/reoxygenation injury are mediated by PKCε. Copyright © 2014 John Wiley & Sons, Ltd.     

The effects of quercetin protect cardiomyocytes from A/R injury is related to its capability to increasing expression and activity of PKCε protein

Quercetin is a ubiquitous flavonoid found in vegetable foods. Epidemiological and animal studies have reported an inverse association between quercetin intakes and occurrence and development of various cardiovascular diseases. Some researchers have inferred that the mechanisms of quercetin to protect cardiomyocytes from ischemia/reperfusion injury may be involved in modulation of intracellular signal pathways and regulation of proteins expression beyond its antioxidant activity. The aim of this study was to investigate whether quercetin protect cardiomyocytes from anoxia/reoxygenation injury through PKCε pathway. Neonatal rat primary cardiomyocytes were pretreated with quercetin or quercetin plus εV1-2, a selective PKCε inhibitor, prior to A/R treatment. Western blotting analysis showed that the level of PKCε and phosphor-PKCε Ser297 in the quercetin pretreatment group were all increased significantly compared to the control or A/R group. Subsequent assays showed that pretreated with quercetin could increase the viability of neonatal rat primary cardiomyocytes suffered A/R, decrease the apoptosis and ROS and alleviate the loss of mitochondrial membrane potential induced by A/R injury. However, the protective effects of quercetin disappeared in the group pretreated with εV1-2. Thus, for the first time, we revealed that one of the mechanisms of quercetin protecting cardiomyocytes from A/R injury might be increase the expression of PKCε protein and then enhance the activity of its downstream pathway.     

UCP2 protect the heart from myocardial ischemia/reperfusion injury via induction of mitochondrial autophagy

Uncoupling protein 2 (UCP2), located in the mitochondrial inner membrane, is a predominant isoform of UCP that expressed in the heart and other tissues of human and rodent tissues. Nevertheless, its functional role during myocardial ischemia/reperfusion (I/R) is not entirely understood. Ischemic preconditioning (IPC) remarkably improved postischemic functional recovery followed by reduced lactate dehydrogenase (LDH) release with simultaneous upregulation of UCP2 in perfused myocardium. We then investigated the role of UCP2 in IPC-afforded cardioprotective effects on myocardial I/R injury with adenovirus-mediated in vivo UCP2 overexpression (AdUCP2) and knockdown (AdshUCP2). IPC-induced protective effects were mimicked by UCP2 overexpression, while which were abolished with silencing UCP2. Mechanistically, UCP2 overexpression significantly reinforced I/R-induced mitochondrial autophagy (mitophagy), as measured by biochemical hallmarks of mitochondrial autophagy. Moreover, primary cardiomyocytes infected with AdUCP2 increased simulated ischemia/reperfusion (sI/R)-induced mitophagy and therefore reversed impaired mitochondrial function. Finally, suppression of mitophagy with mdivi-1 in cultured cardiomyocytes abolished UCP2-afforded protective effect on sI/R-induced mitochondrial dysfunction and cell death. Our data identify a critical role for UCP2 against myocardial I/R injury through preventing the mitochondrial dysfunction through reinforcing mitophagy. Our findings reveal novel mechanisms of UCP2 in the cardioprotective effects during myocardial I/R.     

Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation

An increasing number of investigations including human studies demonstrate that pharmacological ischaemic preconditioning is a viable way to protect the heart from myocardial ischaemia/reperfusion (I/R) injury. This study investigated the role of hydroxychloroquine (HCQ) in the heart during I/R injury. In vitro and in vivo models of myocardial I/R injury were used to assess the effects of HCQ. It was found that HCQ was protective in neonatal rat cardiomyocytes through inhibition of apoptosis, measured by TUNEL and cleaved caspase-3. This protection in vitro was mediated through enhancement of ERK1/2 phosphorylation mediated by HCQ in a dose-dependent fashion. A decrease in infarct size was observed in an in vivo model of myocardial I/R injury in HCQ treated animals and furthermore this protection was blocked in the presence of the ERK1/2 inhibitor U0126. For the first time, we have shown that HCQ promotes a preconditioning like protection in an in vivo simulated rat myocardial I/R injury model. Moreover, it was shown that HCQ is protective via enhanced phosphorylation of the pro-survival kinase ERK1/2.     

A Synergistic Role of Hyperthermic and Pharmacological Preconditioning to Protect Astrocytes Against Ischemia/Reperfusion Injury

Recent studies provide solid evidence for the importance to delineate the co-relationship between preconditioning stimuli and therapeutic efficacy of drugs commonly used in clinic. However, very little is known about this important topic. In the present study, we investigated the effects of hyperthermia on the protective role of ginkgolides on astrocytes against ischemia/reperfusion (I/R) injury and also evaluated the effects of the timing of co-treatment of hyperthermia with ginkgolides on astrocytes against the I/R injury. We demonstrated that there is a synergistic action between hyperthermic and pharmacological preconditioning to protect astrocytes against the I/R injury. Our findings also showed that astrocytes have completely different responses to the treatment with hyperthermia or ginkgolides alone or co-treatment together at different stages of the I/R process. Hyperthermic preconditioning before the I/R can protect astrocytes against the I/R injury. However, if treated in the ischemia and reperfusion stage, hyperthermia exacerbates the cell injury and significantly attenuates the protective effectiveness of ginkgolides. These findings imply that the timing of treatment with hypothermia and/or ginkgolides is one of the key factors to determine their protective effects on the cells against the I/R injury.     

Role of protein phosphatases in hypoxic preconditioning

To find a protein kinase C (PKC)-independent preconditioning mechanism, hypoxic preconditioning (HP; i.e., 10-min anoxia and 10-min reoxygenation) was applied to isolated rat hearts before 60-min global ischemia. HP led to improved recovery of developed pressure and reduced end-diastolic pressure in the left ventricle during reperfusion. Protection was unaffected by the PKC inhibitor bisindolylmaleimide (BIM; 1 micromol/l). It was abolished by the inhibitor of protein phosphatases 1 and 2A cantharidin (20 or 5 micromol/l) and partially enhanced by the inhibitor of protein phosphatase 2A okadaic acid (5 nmol/l). In adult rat cardiomyocytes treated with BIM and exposed to 60-min simulated ischemia (anoxia, extracellular pH 6.4), HP led to attenuation of anoxic Na(+)/Ca(2+) overload and of hypercontracture, which developed on reoxygenation. This protection was prevented by treatment with cantharidin but not with okadaic acid. In conclusion, HP exerts PKC-independent protection on ischemic-reperfused rat hearts and cardiomyocytes. Protein phosphatase 1 seems a mediator of this protective mechanism.